At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed May 11, 2026 at 08:30 ET
Fate Therapeutics presented clinical and preclinical data at ASGCT 2026 for its off-the-shelf iPSC-derived CAR T-cell programs. FT819 showed 3/3 SLE patients achieving SRI-4 and 2/3 achieving LLDAS with durable B-cell remodeling up to 12 months without conditioning chemotherapy. Preclinical data for FT839 and FT836 demonstrated broad depletion of pathogenic cells and synergy with standard-of-care therapies. The data supports the company's platform approach to eliminate conditioning chemotherapy, potentially expanding patient access.
- FT819: 3/3 SLE patients achieved SRI-4, 2/3 achieved LLDAS at dose level 1 without conditioning chemotherapy.
- FT819: 79% average depletion of major B cell clones lasting up to 12 months post single dose.
- FT839 preclinical: >99% depletion of B cells, plasmablasts, plasma cells; >90% depletion of activated T cells in RA and SLE samples.
- FT839: Persistence enhanced ~60x vs. unmodified CAR T via Sword and Shield technology.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access